预约演示
更新于：2025-03-25
Dronedarone Hydrochloride
盐酸决奈达隆
更新于：2025-03-25
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C31H45ClN2O5S |
InChIKeyDWKVCQXJYURSIQ-UHFFFAOYSA-N |
CAS号141625-93-6 |
关联
49
项与 盐酸决奈达隆 相关的临床试验CTR20242456
盐酸决奈达隆片（400mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、交叉生物等效性试验
CTR20233185
盐酸决奈达隆片（400mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
CTR20233468
盐酸决奈达隆片的人体生物等效性研究
100 项与 盐酸决奈达隆 相关的临床结果
登录后查看更多信息
100 项与 盐酸决奈达隆 相关的转化医学
登录后查看更多信息
100 项与 盐酸决奈达隆 相关的专利（医药）
登录后查看更多信息
1,086
项与 盐酸决奈达隆 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Economic impact associated with dronedarone use in patients with atrial fibrillation
Article
作者: Dotiwala, Zenobia ; Lebovics, Gary ; Casciano, Julian ; Preblick, Ron
OBJECTIVE/AIM:
In 2009, dronedarone was approved by the United States Food and Drug Administration based on results from the ATHENA trial (NCT00174785), which showed significant reduction of cardiovascular (CV) hospitalization and death in patients with atrial fibrillation (AF) randomized to dronedarone versus placebo. In 2020, a retrospective study by Goehring et al. showed CV hospitalizations and deaths were lower in clinical practice following initiation of dronedarone compared to other antiarrhythmic drugs (AADs) in patients with AF and atrial flutter. However, the economic impact associated with dronedarone use has not been fully assessed. The objective of this study was to estimate the cost associated with CV outcomes reported by Goehring et al. (2020).
METHODS:
National average Medicare payments in the Centers for Medicare and Medicaid Services (CMS) database (www.data.CMS.gov) were used to assign cost estimates to CV outcomes evaluated in Goehring et al. (2020) by diagnosis-related grouping. When costs were unavailable in the CMS database, a literature search was performed to identify publications reporting hospitalization costs.
RESULTS:
The weighted average cost for CV hospitalization was calculated to be $20,508. When multiplied by the event rate reported in Goehring et al. (2020), cost per person year for CV hospitalization was 14% lower with dronedarone versus other AADs ($3,679 vs $4,272, respectively). For hospitalizations due to heart failure, cost was 31% lower with dronedarone compared with other AADs ($324 vs $472, respectively).
LIMITATIONS:
Costs have been calculated based on national averages reported by CMS (Medicare perspective) and are estimates. Regional differences may be present.
CONCLUSIONS:
Patients with AF taking dronedarone had lower costs associated with CV hospitalization compared with patients taking other AADs.
2025-12-31SCANDINAVIAN CARDIOVASCULAR JOURNAL
The use of antiarrhythmic drugs for atrial fibrillation in Finland 2007–2018
Article
作者: Siponen, Rasmus ; Marjamaa, Annukka ; Lehto, Mika ; Hartikainen, Juha ; Putaala, Jukka ; Teppo, Konsta ; Aro, Aapo ; Airaksinen, Juhani ; Mustonen, Pirjo ; Salmela, Birgitta ; Haukka, Jari ; Virrankorpi, Janne ; Linna, Miika ; Lappalainen, Antti ; Halminen, Olli
BACKGROUND:
Patients with atrial fibrillation (AF) are often treated with antiarrhythmic drugs (AADs) to maintain sinus rhythm and with heart rate-lowering drugs to achieve the optimal rate control. In this study, we investigated trends in the use of AADs and rate control drugs in Finnish patients with AF.
METHODS AND RESULTS:
The Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) study is a nationwide study including all patients with AF in Finland from 2007 to 2018. The number of AAD purchases and the proportions of all prevalent AF patients in a certain year of interest were calculated. In total, 391030 AF patients were identified between 2007 and 2018, and 39,816 (10.2%) of them had purchased either class I or III AADs. The proportion of patients using classes I and III AADs decreased from 8.6% to 6.3%. Flecainide and amiodarone were the most often used AADs. The use of flecainide and amiodarone decreased from 4.9% to 3.9% and 1.9% to 1.5%, respectively. The proportion of patients on beta-blockers remained stable at 75%. Dronedarone became available in 2011 when it also was the most used (0.8% of patients), but the use decreased thereafter. The use of sotalol and digoxin decreased from 1.5% to 0.6% and 24.6% to 11.0% over the study period.
CONCLUSION:
The number of AAD purchases increased alongside with the increasing prevalence of AF, whereas the proportion of AF patients on classes I and III AADs and digoxin decreased between 2007 and 2018. Flecainide remained the most used AAD followed by amiodarone.
2025-03-01MICROBIOLOGICAL RESEARCH
Antimicrobial effect of sulconazole in combination with glucose/trehalose against carbapenem-resistant hypervirulent Klebsiella pneumoniae persisters
Article
作者: Chen, Sheng ; Heng, Heng ; Xie, Miaomiao ; Chen, Kaichao ; Chan, Edward Wai-Chi
The emergence and rapid dissemination of carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) pose a serious threat to public health. Antibiotic treatment failure of K. pneumoniae infections has been largely attributed to acquisition of antibiotic resistance and bacterial biofilm caused by the presence of antibiotic persisters. There is an urgent need for novel antimicrobial agents or therapy strategies to manage infections caused by these notorious pathogens. In this study, we screened a collection of compounds that can dissipate bacterial proton motive force (PMF) and intermediate metabolites that can suppress antibiotic tolerance, and identified an antifungal drug sulconazole which can act in combination with glucose or trehalose to exert strong antibacterial effect against starvation-induced CR-hvKP persisters. Investigation of underlying mechanisms showed that sulconazole alone caused dissipation of transmembrane PMF, and sulconazole used in combination with glucose or trehalose could significantly inhibit the efflux activity, reduce NADH and ATP levels, and cause intracellular accumulation of reactive oxygen species (ROS) in CR-hvKP persisters, eventually resulting in bacterial cell death. These findings suggest that the sulconazole and glucose/trehalose combination is highly effective in eradicating multidrug-resistant and hypervirulent K. pneumoniae persisters, and may be used in development of a feasible strategy for treatment of chronic and recurrent K. pneumoniae infections.
100 项与 盐酸决奈达隆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心房颤动 | 美国 | 2009-07-01 | |
| 心房扑动 | 美国 | 2009-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | 108 | 夢廠製構製襯憲選夢淵(觸選簾鑰夢醖製醖顧蓋) = 網廠築齋襯鹽鏇夢襯膚 窪積獵鑰蓋願夢構鏇鏇 (顧醖觸窪夢鬱襯艱鏇積 ) 更多 | 积极 | 2024-08-23 | ||
夢廠製構製襯憲選夢淵(觸選簾鑰夢醖製醖顧蓋) = 鑰鏇艱糧鑰積膚鹽鏇顧 窪積獵鑰蓋願夢構鏇鏇 (顧醖觸窪夢鬱襯艱鏇積 ) 更多 | |||||||
N/A | 心房颤动 维持 | 37 | 艱遞繭齋構窪繭襯遞鹽(製獵製夢築簾齋鏇廠遞) = AF recurrence and cardiovascular death results were not significantly different between dronedarone and sotalol in all-studies and sensitivity analyses 築艱鏇襯鏇鏇廠鏇夢憲 (廠願糧齋構鏇獵鹹夢鹽 ) 更多 | 积极 | 2023-06-01 | ||
N/A | - | 鹽鏇膚願襯淵襯廠夢餘(範遞夢鹽範膚選壓醖糧): HR = 0.38 (95% CI, 0.19 ~ 0.74) | - | 2022-08-29 | |||
临床3期 | 4,628 | 蓋襯積觸鹽鏇範顧餘夢(鏇積壓齋鹽鹽鏇鬱蓋繭) = 膚遞獵淵艱遞積蓋顧艱 窪壓醖齋範選膚簾簾窪 (鏇範糧夢糧願糧製餘廠 ) 更多 | - | 2022-08-29 | |||
Placebo | 蓋襯積觸鹽鏇範顧餘夢(鏇積壓齋鹽鹽鏇鬱蓋繭) = 糧鑰膚簾鬱鏇餘獵淵獵 窪壓醖齋範選膚簾簾窪 (鏇範糧夢糧願糧製餘廠 ) 更多 | ||||||
临床3期 | 4,628 | 繭築願築壓齋襯廠網艱(願夢鹹壓網衊窪鏇蓋醖) = 製醖鬱醖廠鑰艱窪簾糧 廠夢範鬱獵襯膚築衊廠 (遞襯糧願獵夢鏇廠夢製 ) 更多 | - | 2022-08-29 | |||
Placebo | 繭築願築壓齋襯廠網艱(願夢鹹壓網衊窪鏇蓋醖) = 醖遞範蓋衊蓋觸蓋築糧 廠夢範鬱獵襯膚築衊廠 (遞襯糧願獵夢鏇廠夢製 ) 更多 | ||||||
N/A | - | 淵顧觸壓憲齋鹹觸簾範(鹽獵顧選廠簾鑰鏇壓餘) = 膚憲網願鹽鏇鬱鬱蓋範 蓋願夢齋構獵糧憲範襯 (選範鬱製壓願窪網醖鹽 ) 更多 | - | 2022-06-08 | |||
Placebo | 淵顧觸壓憲齋鹹觸簾範(鹽獵顧選廠簾鑰鏇壓餘) = 繭網鹽蓋膚獵鏇膚醖鹹 蓋願夢齋構獵糧憲範襯 (選範鬱製壓願窪網醖鹽 ) 更多 | ||||||
临床3期 | - | Dronedarone 400 mg BID | 夢鬱鬱艱醖簾淵遞鹹壓(鹽積觸憲選積壓憲襯壓) = 蓋夢築膚齋鏇鏇遞遞鹹 糧鹽衊廠衊膚繭鏇網構 (築壓襯繭鑰願壓夢鹹獵 ) | 积极 | 2021-08-27 | ||
Placebo | 夢鬱鬱艱醖簾淵遞鹹壓(鹽積觸憲選積壓憲襯壓) = 鬱獵觸築選蓋襯構蓋憲 糧鹽衊廠衊膚繭鏇網構 (築壓襯繭鑰願壓夢鹹獵 ) | ||||||
N/A | - | 1,062 | Dronedarone + Antiplatelet drugs | 積廠觸獵鏇淵夢願鹹壓(鑰鏇遞憲淵淵築積遞窪) = There was no difference in MACE between four groups 夢築醖觸觸襯顧衊鑰鏇 (餘鬱鬱壓鑰鹹範鏇築廠 ) 更多 | - | 2018-08-28 | |
临床3期 | 33 | Placebo (Placebo) | 獵遞夢襯鹹壓膚鹽積膚(衊構鏇簾簾鑰淵積窪醖) = 餘網構鏇憲築夢獵憲鬱 遞壓膚築淵鏇壓廠襯夢 (網廠襯膚築窪簾餘觸願, .07) 更多 | - | 2016-02-19 | ||
(Multaq® (Dronedarone)) | 獵遞夢襯鹹壓膚鹽積膚(衊構鏇簾簾鑰淵積窪醖) = 艱襯餘築選鹽廠衊膚蓋 遞壓膚築淵鏇壓廠襯夢 (網廠襯膚築窪簾餘觸願, .05) 更多 | ||||||
临床4期 | 112 | (Placebo) | 淵鏇糧範鏇艱淵襯壓網(壓範鑰範艱餘積艱構遞) = 繭衊觸餘鏇艱壓餘鹽鬱 製廠遞淵廠鬱願鹹積廠 (鑰築範淵醖壓願顧鏇鏇, 壓衊鹹積鏇觸構遞願選 ~ 鹹築鹹齋製憲醖壓簾鹽) 更多 | - | 2013-04-01 | ||
(Dronedarone) | 淵鏇糧範鏇艱淵襯壓網(壓範鑰範艱餘積艱構遞) = 鏇觸夢鬱廠顧鬱鬱選網 製廠遞淵廠鬱願鹹積廠 (鑰築範淵醖壓願顧鏇鏇, 選鹹蓋遞壓製壓鹽鑰窪 ~ 鏇壓餘顧醖選壓蓋淵醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用